Skip to main content
Clinical Trials/NL-OMON47096
NL-OMON47096
Completed
Not Applicable

Molecular imaging of coronary plaque vulnerability using 18F-fluorocholine PET-MRI in patients with coronary artery disease - 18F-fluorocholine PET-MR imaging of coronary plaque vulnerability

Medisch Universitair Ziekenhuis Maastricht0 sites35 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
35
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • Protocol optimization (stable AP patients included at MUMC\+: additional PET\-MRI);\* Diagnosed with stable angina pectoris and scheduled for a PCI procedure at the MUMC
  • \* Minimum age of 18 years
  • \* Mentally competent
  • \* Having provided informed written consent ;Patients included at Viecuri hospital: additional PET\-MRI and OCT;\* NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital
  • \* Currently stable and scheduled for another PCI at the VieCuri hospital to stent another coronary vessel
  • \* Able to visit the MUMC by own transport / train for PET\-MR imaging before the new PCI procedure
  • \* Minimum age of 18 years
  • \* Mentally competent
  • \* Having provided informed written consent
  • Patients included at MUMC\+: additional PET\-MRI;\* Recently diagnosed with NSTEMI and scheduled for a PCI at the MUMC

Exclusion Criteria

  • \* Conservatively managed patients who are not scheduled for percutaneous coronary intervention (PCI)
  • \* Patients requiring PCI \< 24 hours after admission
  • \* Hemodynamic instability and cardiogenic shock (mean arterial pressure \< 60 mmHg)
  • \* Severe heart failure (Killip Class \* III)
  • \* Chest pain highly suggestive of non\-cardiac origin (as judged by the cardiac
  • physician/cardiologist)
  • \* Atrial fibrillation with ventricular rate \*100 beats per minute (bpm)
  • \* Tachycardia (\* 100/bpm)
  • \* Pregnancy
  • \* Breast feeding women

Outcomes

Primary Outcomes

Not specified

Similar Trials